Virios Therapeutics, Inc.
VIRI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,521 | $2,570 | $2,437 | $3,530 |
| G&A Expenses | $1,288 | $1,353 | $1,993 | $8,694 |
| SG&A Expenses | $1,288 | $1,353 | $1,993 | $8,694 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15,809 | $3,923 | $4,430 | $12,224 |
| Operating Income | -$15,809 | -$3,923 | -$4,430 | -$12,224 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $63 | $116 | -$6,304 | -$123 |
| Pre-Tax Income | -$15,746 | -$3,807 | -$10,734 | -$12,347 |
| Tax Expense | -$1 | $0 | $191 | $2 |
| Net Income | -$15,745 | -$3,807 | -$12,182 | -$12,859 |
| % Margin | – | – | – | – |
| EPS | -8.2 | -1.99 | -8.45 | -12.35 |
| % Growth | -312.1% | 76.4% | 31.6% | – |
| EPS Diluted | -8.2 | -1.99 | -8.45 | -12.35 |
| Weighted Avg Shares Out | 1,919 | 1,911 | 1,442 | 1,028 |
| Weighted Avg Shares Out Dil | 1,919 | 1,911 | 1,442 | 1,028 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $111 | $147 | $92 |
| Depreciation & Amortization | $2 | $0 | $0 | -$2 |
| EBITDA | -$15,744 | -$3,923 | -$4,430 | -$12,224 |
| % Margin | – | – | – | – |